Mind-Altering Drugs News StoriesExcerpts of Key Mind-Altering Drugs News Stories in Major Media
Note: This comprehensive list of mind-altering drugs news stories is usually updated once a week. Explore our full index to revealing excerpts of key major media news stories on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.
$452 million: That's the value of retail products containing imported hemp that were sold in the United States in 2011. While a cousin of marijuana, the plant can't get you high. Instead, it can be used to make clothes, horse bedding, auto parts, soap and even concrete. But thanks to it being classified like all cannabis plants as a Schedule I substance - the same as heroin - the U.S. hemp crop is precisely zero. If you want to grow hemp and avoid a jail sentence, you need a permit from the Drug Enforcement Administration.
Note: Many have suspected that hemp was outlawed along with marijuana to block competition with lumber and other industries. To see a 1938 Popular Mechanics article touting hemp as the "new billion dollar crop," click here.
More than 7 million Americans suffer from PTSD, and by most estimates, only half of them -- at best -- are ever cured. A decade ago, the widely acknowledged need for better treatments opened the door to [South Carolina psychiatrist Dr. Michael] Mithoefer and his unconventional approach. By ... February 2005, the soft-spoken, ponytailed Mithoefer had managed to convince the Drug Enforcement Administration to green-light a study of Ecstasy as an adjunct to psychotherapy. He'd gotten the 3,4-methylenedioxy-methylamphetamine (MDMA) -- the chemical name for pure Ecstasy -- from Rick Doblin, the founder of a MAPS, the Multidisciplinary Association for Psychedelic Studies. The group's stated purpose is to develop "medical, legal and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana." It wants to turn mind-altering drugs like Ecstasy into prescription medicine. To win broader acceptance for MDMA -- and for cousins like LSD and psilocybin, the mind-altering compound in so-called magic mushrooms -- "the medical route was the only route. Everything else was blocked." That meant a formal plan for drug development: study protocols, institutional review boards and the rest. Mithoefer, a University of Virginia-trained clinician who specializes in trauma and had a long-running interest in MDMA, was the perfect partner.
Note: To watch a CNN video clip on this showing remarkable success in treating PTSD, click here. For deeply revealing reports from reliable major media sources on beneficial mind-altering drugs, click here.
Hundreds of Iraq and Afghanistan veterans with post-traumatic stress have recently contacted a husband-and-wife team who work in suburban South Carolina to seek help. Many are desperate, pleading for treatment and willing to travel to get it. The soldiers have no interest in traditional talking cures or prescription drugs that have given them little relief. They are lining up to try an alternative: MDMA, better known as Ecstasy, a party drug that surfaced in the 1980s and ’90s that can induce pulses of euphoria and a radiating affection. Government regulators criminalized the drug in 1985, placing it on a list of prohibited substances that includes heroin and LSD. But in recent years, regulators have licensed a small number of labs to produce MDMA for research purposes. In a paper posted online ... by the Journal of Psychopharmacology, Michael and Ann Mithoefer, the husband-and-wife team offering the treatment — which combines psychotherapy with a dose of MDMA — write that they found 15 of 21 people who recovered from severe post-traumatic stress in the therapy in the early 2000s reported minor to virtually no symptoms today. The Mithoefers — he is a psychiatrist and she is a nurse — collaborated on the study with researchers at the Medical University of South Carolina and the nonprofit Multidisciplinary Association for Psychedelic Studies. The patients in this group included mostly rape victims, and experts familiar with the work cautioned that it was preliminary, based on small numbers, and its applicability to war trauma entirely unknown.
Note: For the paper on this remarkable study published published online in the Journal of Psychopharmacology, click here. For deeply revealing reports from reliable major media sources on beneficial mind-altering drugs, click here.
Massachusetts voters in 2˝ weeks will consider becoming the 18th state to legalize the use of marijuana for medical purposes. Individual doctors and patient advocacy groups, including the AIDS Action Committee of Massachusetts and the state chapter of the Leukemia and Lymphoma Society, have endorsed the ballot question, saying marijuana can help patients and is available now. To study marijuana, researchers must be licensed by the US Drug Enforcement Administration and get access to marijuana grown at the University of Mississippi, which contracts with the National Institute on Drug Abuse to produce the only federally sanctioned supply. That process can prove onerous, if not impossible, acting as a deterrent for those who might want to study marijuana’s benefits, some researchers said. In 2000, the University of California created the Center for Medicinal Cannabis Research, with $9 million from the state. Dr. Igor Grant, the center’s director, ... and colleagues have completed the most comprehensive research to date of the effects of marijuana in patients, including studies that were randomized and double-blind, gold standards in research. Four studies found the drug to be useful in treating pain. Three were in patients with HIV who had pain resulting from damage to their nervous system. Another study found that marijuana reduced muscle stiffness in patients with multiple sclerosis.
Note: For deeply revealing reports from reliable major media sources on mind-altering drugs, click here.
Until recently, prescribing Ecstasy, mescaline or magic mushrooms has been a guaranteed way for a psychiatrist to lose his research funding, his job or even his liberty. But now, scientists are beginning to suspect that such illegal drugs may be the key to treating a range of intractable illnesses, from post-traumatic stress disorder to depression. These chemicals [include] the psychedelic drugs psilocybin, derived from magic mushrooms, and LSD, as well as Ecstasy. A series of studies performed in Britain and the US is beginning to tease out their potential benefits. “People become very emotionally tender on Ecstasy, which makes you more responsive to psychotherapy,” explains Dr Robin Carhart-Harris. [In] volunteers given the ... drug, the area of their brain involved in positive memories became more active, while another processing negative memories was damped down. “We think this would make it easier for patients to revisit a traumatic memory and overwrite or control it,” says Carhart-Harris. Earlier studies have made surprising discoveries about what psilocybin, a class-A drug in Britain, was doing in the brain. These in turn could lead to new treatments for depression and agonising cluster headaches. This may all sound radical, or even dangerous – yet half a century ago, research into the effects of psychedelic drugs was widespread and respectable. More than 1,000 papers were published looking at ways that psychiatrists could help patients with hallucinogenic chemicals.
Note: For deeply revealing reports from reliable major media sources on mind-altering drugs, click here.
Mounting evidence shows ‘cannabinoids’ in marijuana slow cancer growth, inhibit formation of new blood cells that feed a tumor, and help manage pain, fatigue, nausea, and other side effects. Peer-reviewed studies in several countries ... show that THC and other marijuana-derived compounds, known as “cannabinoids,” are effective not only for cancer-symptom management (nausea, pain, loss of appetite, fatigue), they also confer a direct antitumoral effect. A team of Spanish scientists led by Manuel Guzman conducted the first clinical trial assessing the antitumoral action of THC on human beings. THC treatment was associated with significantly reduced tumor cell proliferation in every test subject. Harvard University scientists reported that THC slows tumor growth in common lung cancer and “significantly reduces the ability of the cancer to spread.” What’s more ... THC selectively targets and destroys tumor cells while leaving healthy cells unscathed. Conventional chemotherapy drugs, by contrast, are highly toxic; they indiscriminately damage the brain and body. There is mounting evidence ... that cannabinoids “represent a new class of anticancer drugs that retard cancer growth, inhibit angiogenesis [the formation of new blood cells that feed a tumor] and the metastatic spreading of cancer cells.” Within the medical science community, the discovery that cannabinoids have anti-tumoral properties is increasingly recognized as a seminal advancement in cancer therapeutics.
Note: Yet treatment with cannabinoids continues to be largely illegal in the US. For an informative 15-minute documentary on the health benefits of juicing raw cannabis, click here. For deeply revealing reports from reliable major media sources on promising cancer-cure research, click here.
Research into ... Schedule I drugs like MDMA (ecstasy), LSD and magic mushrooms ... requires not only a high level of security, but also that the institutions involved buy a licence costing several thousand pounds not required for researching other drugs. Paradoxically, the other schedules include more harmful substances such as heroin. Funders often shy away from such research because of the red tape, associated higher costs, and the perception that it is possible to be stigmatised for supporting such work. Research into a Schedule I drug like MDMA has potential both to help our understanding of how drugs affect the brain, and provide those who take them with better harm-reduction information. It also helps us understand how we can make drugs work normally, advancing our treatment of brain disorders. Some Schedule I drugs have huge potential for serious conditions where treatment is currently inadequate, including addiction and depression. Frustratingly, almost no research has been carried out since current regulations came into force in 1971. And the situation is about to get worse; the government's new temporary drug control orders ... automatically puts new substances under Schedule I for the year that they are controlled. The likelihood of the drug then being downgraded is very remote, given that research will be practically impossible, especially within the year's timeframe.
Note: For deeply revealing reports from reliable major media sources on mind-altering drugs, click here.
Three and a half years ago, on my 62nd birthday, doctors discovered a mass on my pancreas. It turned out to be Stage 3 pancreatic cancer. I was told I would be dead in four to six months. Today I am in that rare coterie of people who have survived this long with the disease. But I did not foresee that after having dedicated myself for 40 years to a life of the law, including more than two decades as a New York State judge, my quest for ameliorative and palliative care would lead me to marijuana. My survival has demanded an enormous price, including months of chemotherapy, radiation hell and brutal surgery. Inhaled marijuana is the only medicine that gives me some relief from nausea, stimulates my appetite, and makes it easier to fall asleep. The oral synthetic substitute, Marinol, prescribed by my doctors, was useless. Rather than watch the agony of my suffering, friends have chosen, at some personal risk, to provide the substance. I find a few puffs of marijuana before dinner gives me ammunition in the battle to eat. A few more puffs at bedtime permits desperately needed sleep. This is not a law-and-order issue; it is a medical and a human rights issue. Being treated at Memorial Sloan Kettering Cancer Center, I am receiving the absolute gold standard of medical care. But doctors cannot be expected to do what the law prohibits, even when they know it is in the best interests of their patients. When palliative care is understood as a fundamental human and medical right, marijuana for medical use should be beyond controversy.
Note: The author is Gustin L. Reichbach, who is a justice of the New York State Supreme Court in Brooklyn. For lots more from reliable sources on the benefits of many mind-altering drugs, click here.
Since the 1960s a disparate group of scientists and former drug addicts have been advocating a radical treatment for addiction - a hallucinogen called ibogaine, derived from an African plant, that in some cases seems to obliterate withdrawal symptoms from heroin, cocaine and alcohol. So why isn't it widely used? The drug, derived from the root of a central African plant called iboga, had been used for centuries by the Bwiti people of Gabon and Cameroon, as part of a tribal initiation ceremony. But it wasn't until 1962, when a young heroin addict called Howard Lotsof stumbled upon ibogaine, that its value as an addiction treatment was uncovered. Lotsof took it to get high but when the hallucinogenic effects wore off, he realised he no longer had the compulsion to take heroin. He became convinced that he had found the solution to addiction and dedicated much of his life to promoting ibogaine as a treatment. Ibogaine affects the brain in two distinct ways. The first is metabolic. It creates a protein that blocks receptors in the brain that trigger cravings, stopping the symptoms of withdrawal. With normal detox this process can take months. Its second effect is much less understood. It seems to inspire a dream-like state that is intensely introspective, allowing addicts to address issues in their life that they use alcohol or drugs to suppress.
Note: For more news articles from reliable sources on mind-altering drugs, click here.
Recent studies at Harvard, U.C.L.A. [and] John Hopkins have now made it plain that doctors should [soon] be free to offer illicit drugs to patients who are terminally ill, in order to ease their emotional suffering. At Harvard, Dr. John Halpern ... tested MDMA (the street drug Ecstasy) to determine if it would ease the anxieties in two patients with terminal cancer. At U.C.L.A. and Hopkins, Drs. Charles Grob and Roland Griffiths used psilocybin (the active ingredient in hallucinogenic mushrooms) to help cancer patients past their paralyzing, debilitating fears. The results are reportedly consistently good. In many cases, patients are able to cope with their physical pain and psychological turmoil better than before. Some, no doubt, feel the drugs opened doors of perception previously closed to them, allowing them to make peace with their lives and the impending end of their lives. Recent data also show that low doses of the street drug Special K (ketamine), when slowly infused via IV, can instantly [relieve] major depression ... in many patients. And opiates like oxycodone ... are also extremely useful for those patients who ... suffer with unwieldy anxiety that cannot be addressed ... in any other way.
Note: For more news articles from reliable sources on mind-altering drugs, click here.
Charles Grob [is] a psychiatrist and researcher at Harbor-U.C.L.A. Medical Center who [has administered] psilocybin — an active component of magic mushrooms — to end-stage cancer patients to see if it could reduce their fear of death. When the research was completed in 2008 ... the results showed that administering psilocybin to terminally ill subjects could be done safely while reducing the subjects’ anxiety and depression about their impending deaths. Grob’s interest in the power of psychedelics to mitigate mortality’s sting is not just the obsession of one lone researcher. Dr. John Halpern, head of the Laboratory for Integrative Psychiatry at McLean Hospital in Belmont Mass., a psychiatric training hospital for Harvard Medical School, used MDMA — also known as ecstasy — in an effort to ease end-of-life anxieties in two patients with Stage 4 cancer. And there are two ongoing studies using psilocybin with terminal patients, one at New York University’s medical school, led by Stephen Ross, and another at Johns Hopkins Bayview Medical Center, where Roland Griffiths has administered psilocybin to 22 cancer patients and is aiming for a sample size of 44. “This research is in its very early stages,” Grob told me earlier this month, “but we’re getting consistently good results.” Grob and his colleagues are part of a resurgence of scientific interest in the healing power of psychedelics.
Note: For fascinating reports from major media sources on the beneficial uses of psychedelics, click here.
Traditional antidepressants like Prozac work on a group of chemical messengers in the brain called the serotonin system. Researchers once thought that a lack of serotonin was the cause of depression, and that these drugs worked simply by boosting serotonin levels. Recent research suggests a more complicated explanation. Serotonin drugs work by stimulating the birth of new neurons, which eventually form new connections in the brain. Ketamine, in contrast, activates a different chemical system in the brain – the glutamate system. Researcher Ron Duman at Yale thinks ketamine rapidly increases the communication among existing neurons by creating new connections. This is a quicker process than waiting for new neurons to form and accomplishes the same goal of enhancing brain circuit activity. Ketamine has been used for decades as an anesthetic. It also has become a wildly popular but illegal club drug known as "Special K." Mental health researchers got interested in ketamine because of reports that it could make depression vanish almost instantly. Carlos Zarate ... does ketamine research at the NIH. Zarate says patients typically say, "'I feel that something's lifted or feel that I've never been depressed in my life. I feel I can work. I feel I can contribute to society.' And it was a different experience from feeling high. This was feeling that something has been removed."
Note: For many inspiring potential treatment breakthroughs in health issues, click here.
More than half a century ago, author Aldous Huxley titled his book on his experience with hallucinogens The Doors of Perception. Huxley posited that ordinary consciousness represents only a fraction of what the mind can take in. In order to keep us focused on survival, Huxley claimed, the brain must act as a “reducing valve” on the flood of potentially overwhelming sights, sounds and sensations. What remains, Huxley wrote, is a “measly trickle of the kind of consciousness” necessary to “help us to stay alive.” A new study by British researchers supports this theory. It shows for the first time how psilocybin — the drug contained in magic mushrooms — affects the connectivity of the brain. Researchers found that the psychedelic chemical ... does not work by ramping up the brain’s activity as they’d expected. Instead, it reduces it. Under the influence of mushrooms, overall brain activity drops, particularly in certain regions that are densely connected to sensory areas of the brain. When functioning normally, these connective “hubs” appear to help constrain the way we see, hear and experience the world, grounding us in reality. Psilocybin cuts activity in these nodes and severs their connection to other brain areas, allowing the senses to run free. Huxley ... had predicted what turns out to be a key finding of modern neuroscience: many of the human brain’s highest achievements involve preventing actions instead of initiating them, and sifting out useless information rather than collecting and presenting it for conscious consideration.
Note: There are several excellent links in the full article which show promising results of using these plants to improve mental health and more.
The psychedelic drug psilocybin (the active ingredient in “magic mushrooms”) may produce lasting, positive changes in personality, new research finds. People who took the drug showed increases in the key personality dimension of openness — being amenable to new ideas, experiences and perspectives — more than a year later. Researchers led by Katherine MacLean, a postdoctoral student at Johns Hopkins University, analyzed personality data on 52 participants (average age 46) who had participated in the group’s earlier research on the drug. These volunteers took psilocybin during two to five sessions, at various doses, under highly controlled conditions at the hospital. The earlier study had found positive psychological changes — documented by both participants and their family members and other associates — in calmness, happiness and kindness. The new research found that the drug takers also saw long-term changes to their underlying personality. The personality changes also ran counter to those expected as people age. Normally, as people grow older, they become increasingly less open to new ideas and new experiences. In contrast, in participants who experienced had what researchers call a “full mystical experience,” the scientists saw a shift toward increased openness, as though the volunteers had become decades younger. People became more curious and more interested in new ideas and experiences and in trying new things.
The psychedelic drug in magic mushrooms may have lasting medical and spiritual benefits, according to new research from Johns Hopkins School of Medicine. The mushroom-derived hallucinogen, called psilocybin, is known to trigger transformative spiritual states, but at high doses it can also result in "bad trips" marked by terror and panic. "The important point here is that we found the sweet spot where we can optimize the positive persistent effects and avoid some of the fear and anxiety that can occur and can be quite disruptive," says lead author Roland Griffiths, professor of behavioral biology at Hopkins. Giffiths' study involved 18 healthy adults, average age 46. Nearly all the volunteers were college graduates and 78% participated regularly in religious activities; all were interested in spiritual experience. Fourteen months after participating in the study, 94% of those who received the drug said the experiment was one of the top five most meaningful experiences of their lives; 39% said it was the single most meaningful experience. Their friends, family members and colleagues also reported that the psilocybin experience had made the participants calmer, happier and kinder.
A new documentary [has been] produced and aired by Montana PBS, a non-profit publicly-supported broadcasting television service in the United States. Their programme, "Clearing the Smoke", investigates the science of marijuana, [exploring] how cannabis acts on the brain and in the body in medically beneficial ways to treat nausea, pain, epilepsy and possibly even cancer. This programme includes extensive interviews with patients, doctors, [and] researchers, and skeptics detail the promises and the limitations of medicinal cannabis. Marijuana use is illegal throughout many countries of the world for reasons that are not clear. This video is important because it mainly investigates the scientific basis underlying the medical benefits of marijuana use instead of focusing on the social, political and legal hysteria that have been attached to it. The paper mentioned in this video, Marijuana Reconsidered, was published in book form and can be purchased from Amazon. The author, Dr Grinspoon, is the world's leading authority on marijuana. In this book, Dr Grinspoon examines -- and debunks -- many of the common misconceptions about marijuana.
Fifty years ago, Eric Gow had a baffling and unexplained experience. As a 19-year-old sailor, he remembers going to a clandestine military establishment, where he was given something to drink in a sherry glass and experienced vivid hallucinations. Other servicemen also remember tripping: one thought he was seeing tigers jumping out of a wall, while another recalls faces "with eyes running down their cheeks, Salvador Dalí-style". Mr Gow and another serviceman had volunteered to take part in what they thought was research to find a cure for the common cold. Mr Gow felt that the government had never explained what happened to him. But now he has received an official admission for the first time, confirmed last night, that the intelligence agency MI6 tested LSD on servicemen. One of the scientists involved at the time suggested that the experiments were stopped because it was feared that the acid could produce "suicidal tendencies". MI6, known formally as the Secret Intelligence Service (SIS) and responsible for spying operations abroad, carried out the tests in the cold war in an attempt to uncover a "truth drug" which would make prisoners talk against their will in interrogations. In parallel experiments, the CIA infamously tested LSD and other drugs on unwitting human subjects in a 20-year search to uncover mind-manipulation techniques. The trials were widely criticised when they came to light in the 1970s.
Note: For key reports from major media sources on CIA experimentation on unwitting subjects, click here.
The psychedelic drug psilocybin, the active ingredient in "magic mushrooms," can improve mood and reduce anxiety and depression in terminal cancer patients, Los Angeles researchers reported [on September 6]. A single modest dose of the hallucinogen ... can improve patients' functioning for as long as six months, allowing them to spend their last days with more peace, researchers said. Dr. Charles Grob, a psychiatrist at Harbor- UCLA Medical Center and the Los Angeles Biomedical Research Institute ... and his colleagues studied 12 patients, ages 36 to 58, with advanced-stage cancer and anxiety resulting from their diagnoses. The patients were given a relatively low dose of psilocybin, 0.2 milligram per kilogram of body weight. Nonetheless, the team reported in the Archives of General Psychiatry, all patients reported a significant improvement in mood for at least two weeks after the psilocybin treatment and up to a six-month improvement on a scale that measures depression and anxiety. Most also reported a decreased need for narcotic pain relievers. No adverse reactions were observed. These types of patients normally do not respond well to psychological therapy, Grob said, but his study showed that the drug has "great promise for alleviating anxiety and other psychiatric symptoms."
Note: For many hope-inspiring reports from reliable sources on new cancer coping strategies and possible cures, click here.
Nearly 60 years ago, a French town was hit by a sudden outbreak of hallucinations, which left five people dead and many seriously ill. On 16 August 1951, postman Leon Armunier was doing his rounds in the southern French town of Pont-Saint-Esprit when he was suddenly overwhelmed by nausea and wild hallucinations. "It was terrible. I had the sensation of shrinking and shrinking, and the fire and the serpents coiling around my arms," he remembers. Leon, now 87, fell off his bike and was taken to the hospital in Avignon. Over the coming days, dozens of other people in the town fell prey to similar symptoms. Doctors at the time concluded that bread at one of the town's bakeries had become contaminated by ergot, a poisonous fungus that occurs naturally on rye. That view remained largely unchallenged until 2009, when an American investigative journalist, Hank Albarelli, revealed a CIA document labelled: "Re: Pont-Saint-Esprit and F.Olson Files. SO Span/France Operation file, inclusive Olson. Intel files. Hand carry to Belin - tell him to see to it that these are buried." F. Olson is Frank Olson, a CIA scientist who, at the time of the Pont St Esprit incident, led research for the agency into the drug LSD. David Belin, meanwhile, was executive director of the Rockefeller Commission created by the White House in 1975 to investigate abuses carried out worldwide by the CIA. Albarelli believes the Pont-Saint-Esprit and F. Olson Files, mentioned in the document, would show - if they had not been "buried" - that the CIA was experimenting on the townspeople, by dosing them with LSD.
Note: Frank Olson later had his drink spiked with LSD and allegedly committed suicide shortly thereafter. Yet many believe he was "suicided" as he was having misgivings about his involvement in this program and considering spilling the beans, as reported in this news article. For an overview of CIA mind-control experimentation, click here.
Scientists are taking a new look at hallucinogens, which became taboo among regulators after enthusiasts like Timothy Leary promoted them in the 1960s with the slogan ďż˝Turn on, tune in, drop out.ďż˝ Now, using rigorous protocols and safeguards, scientists have won permission to study once again the drugsďż˝ potential for treating mental problems and illuminating the nature of consciousness. Researchers from around the world are gathering this week in San Jose, Calif., for the largest conference on psychedelic science held in the United States in four decades. They plan to discuss studies of psilocybin and other psychedelics for treating depression in cancer patients, obsessive-compulsive disorder, end-of-life anxiety, post-traumatic stress disorder and addiction to drugs or alcohol. Scientists are especially intrigued by the similarities between hallucinogenic experiences and the life-changing revelations reported throughout history by religious mystics and those who meditate. These similarities have been identified in neural imaging studies conducted by Swiss researchers and in experiments led by Roland Griffiths, a professor of behavioral biology at Johns Hopkins. In one of Dr. Griffithsďż˝s first studies, involving 36 people with no serious physical or emotional problems, he and colleagues found that psilocybin could induce what the experimental subjects described as a profound spiritual experience with lasting positive effects for most of them.
Note: For key reports on health issues from reliable sources, click here.
Important Note: Explore our full index to revealing excerpts of key major media news stories on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.